Oryzon Genomics S.A. Total Current Liabilities

Oryzon Genomics S.A. (ORYZF) currently reports a total current liabilities of $11M as of June 2026. That compares with $13M in the prior-year period — down 17.8% year over year. Use the charts on this page to explore Oryzon Genomics S.A.'s total current liabilities history and peer comparisons.

Oryzon Genomics S.A.'s total current liabilities decreased from $13M to $11M — a 17.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Oryzon Genomics S.A. reported $11M in total current liabilities as of June 2026. That compares with $13M in the prior-year period — down 17.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Oryzon Genomics S.A., and consider following ORYZF for alerts when major investors trade the stock.

Oryzon Genomics S.A. is classified in the Healthcare sector. On total current liabilities, it currently shows $11M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ORYZF with unrelated industries.